Major bleeding events in Jordanian patients undergoing percutaneous coronary intervention (PCI): Incidence, associated factors, impact on prognosis, and predictability of the CRUSADE bleeding risk score. Results from the First Jordanian PCI Registry (PCR1)

Mohamad Jarrah, Ayman Hammoudeh1, Osama Okkeh1, Yousef Khader2, Sahem Gharaibeh, Laith Nasser, Amro Rasheed3, Ayed Al-Hindi4, Mohammad Mohealdeen5, Haneen Kharabsheh, Hanan Abunimeh4, Enas Hijjih4, Lina Tashman4, Delia Omar4, Nadeen Kufoof5, on behalf of the First Jordanian PCI Registry Investigators Group

Division of Cardiology, Internal Medicine Department, King Abdullah University Hospital, Jordan University of Science and Technology; Irbid-Jordan
1Interventional Cardiology Service, Istishari Hospital; Amman-Jordan, 2Faculty of Medicine, Jordan University of Science and Technology; Irbid-Jordan
3Department of Cardiology, Islamic Hospital; Amman-Jordan, 4Pharmaceutical Services Department, Ibn Haitham Hospital; Amman-Jordan
5Pharmaceutical Services Department, Arab Medical Center; Amman-Jordan

ABSTRACT

Objective: Determine the incidence of major bleeding events, their risk factors, and their impact on prognosis in Jordanian patients undergoing percutaneous coronary intervention (PCI). Evaluate the ability of the CRUSADE bleeding risk score (BRS) to predict major bleeding.

Methods: Major bleeding events were defined according to the CRUSADE classification and their incidence was evaluated from hospital admission to one year of follow up. The CRUSADE bleeding risk score was calculated for each patient during the index admission. Incidence of major bleeding events was evaluated in each of the bleeding score quintiles. JoPCR1 is a prospective, observational, multicenter registry of consecutive patients who underwent PCI at 12 tertiary care centers in Jordan. A case report form was used to record data prospectively at hospital admission, at discharge, and at 1 and 12 months of follow-up.

Results: The study included 2426 consecutive patients who underwent PCI. During the index hospitalization, major and minor bleeding events occurred in 0.95% and 2.6% of patients, respectively. Multivariate analysis showed that only two variables were significantly associated with major bleeding: female gender (OR=3.7; 95% CI 1.6, 8.5; p=0.002) and past history of cardiovascular disease (OR=2.6; 95% CI 1.1, 5.9; p=0.026). Patients who had in-hospital major bleeding events had higher cardiac mortality during index hospitalization (13.0% vs. 0.7%, p<0.005) and at one year of follow up (13.0% vs. 1.8%, p<0.005) compared to those who had no such events. Receiver operating characteristic curve analysis showed that the CRUSADE BRS has a high ability to predict major bleeding.

Conclusion: Major bleeding events were uncommon in this ME registry of a contemporary cohort of patients undergoing PCI but were associated with a higher mortality rate compared with those who did not have major bleeding events. CRUSADE BRS was highly predictive of the incidence of major bleeding events. (Anatol J Cardiol 2017; 17: 445-51)

Keywords: major bleeding events, percutaneous coronary intervention, CRUSADE bleeding risk score

Introduction

Bleeding is the most important non-ischemic complication after percutaneous coronary intervention (PCI) and can potentially lead to significant mortality and morbidity (1–3). Predicting the risk of major bleeding events in patients undergoing PCI is an essential component of an effective and safe PCI procedure (4, 5). Several bleeding risk scores (BRSs) including the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) BRS have been demonstrated to accurately predict risks of major bleeding events (6–11).

The predictive value of the CRUSADE BRS might not apply to patients admitted with acute coronary syndrome (ACS) and/or undergoing PCI in regions other than those where the risk score was developed or tested due to differences in baseline clinical features and/or availability of medical and invasive therapeutic strategies. The objective of this study [the First Jordanian PCI Registry (JoPCR1)] was to determine the incidence of major bleeding events, their risk factors, and their impact on prognosis in Jordanian patients undergoing PCI. The ability of the CRUSADE BRS to predict major bleeding was also evaluated.
Methods

JoPCR1 is a prospective, observational, multicenter registry of consecutive patients who underwent PCI at 12 tertiary care Amman Surgical Hospital, Amman, Jordan; Arab Medical Center, Amman, Jordan; Essra Hospital, Amman, Jordan; Ibn Haitham Hospital, Amman, Jordan; Islamic Hospital, Amman, Jordan; Istishari Hospital, Amman, Jordan; Jordan Hospital, Amman, Jordan; Jordan University Hospital, Amman, Jordan; Khalidi Medical Center, Amman, Jordan; King Abdullah University Hospital, Irbid, Jordan; Prince Hamza Hospital, Amman, Jordan; Specialty Hospital, Amman, Jordan, in two major cities of Jordan (Amman and Irbid) between January 2013 and February 2014. A case report form was used to record data prospectively at hospital admission, at discharge, and at 1 and 12 months of follow-up. Data were collected during follow-up visits or phone calls to the patient, a household relative, or a primary care physician at 1, 6, and 12 months after discharge. The study was approved by the Institutional Review Board of each participating hospital. Baseline data included clinical, laboratory, electrocardiographic, echocardiographic, and coronary angiographic features. Details of the PCI procedure and its outcome were also recorded. Creatinine clearance (CrCl) was estimated using the Cockcroft-Gault equation (12).

All PCI procedures were performed according to current standard guidelines. The arterial access site, type and number of stents, and the use of intravenous glycoprotein inhibitors (GPI) IIb/IIIa inhibitors were left to the operator’s discretion. All patients received dual oral antiplatelet therapy (aspirin and 300–600 mg clopidogrel or 180 mg ticagrelor loading dose, and a loading dose of unfractionated heparin (100 IU/kg body weight). The activated clotting time was maintained >300 seconds throughout or immediately at the conclusion of the PCI procedure. PCI was indicated for either ACS or stable coronary disease (SC). ACS was classified as (1) acute ST-segment elevation myocardial infarction (STEMI); defined by the presence of cardiac ischemic chest pain, ST-segment elevation of >2 mm in at least 2 contiguous leads on the 12-lead electrocardiogram (ECG), and elevated cardiac biomarkers (troponin or creatinine kinase-myocardial band) greater than the upper limit of the normal, or (2) non-ST elevation ACS (NSTEMI), which included non ST-segment elevation MI (NSTEMI); defined by the presence of cardiac ischemic chest pain, ST-segment depression, inverted T wave or normal ECG, and elevated cardiac biomarkers as above, and (3) unstable angina (UA); defined by the presence of ischemic cardiac pain, ST-segment depression, inverted T wave or normal ECG, and no elevation of cardiac biomarkers on admission and 8–12 hours later. SC was defined by the presence of either (1) chronic stable angina (CSA); i.e., ischemic cardiac pain on effort that did not change in severity for the past 3 months, and absence of resting ECG ischemic changes or elevated cardiac biomarkers, or (2) silent ischemia (SI); defined by the absence of angina in the presence of signs of myocardial ischemia on ECG, echocardiography, or nuclear myocardial scan.

PCI for STEMI was (1) primary, i.e., PCI as reperfusion strategy with no thrombolysis, (2) rescue; after failure of thrombolysis, or (3) elective; after successful thrombolysis. PCI for NSTEMI was (1) urgent, i.e., done within 2 hours after admission for ongoing chest pain, hemodynamic instability, life-threatening ventricular arrhythmia, or heart failure, (2) early invasive; within 24 hours after admission, or (3) invasive; within 24–72 hours after admission.

Major bleeding events were defined according to the CRUSADE study classification (6) and included intracranial hemorrhage, retroperitoneal bleeding, haematocrit (Hct) drop >12% from baseline, any red blood cell (RBC) transfusion when baseline Hct was >28%, or any RBC transfusion when baseline Hct was <28% with witnessed bleeding. Minor bleeding was defined as any non-major bleeding. Cardiac mortality was defined as any death not attributed to a clear noncardiac cause.

The CRUSADE BRS was calculated for each patient by assigning certain number of points for weighted integers of each of the eight independent predictors of in-hospital major bleeding events. These predictors include the patient’s features [gender, diabetes mellitus (DM), and peripheral arterial disease (PAD)], clinical variables [heart rate (HR), systolic blood pressure (SBP), and heart failure], and admission laboratory data (Hct and CrCl). The sum of these points comprises the patient’s score that ranges from 1 to 100 (6). The scores of all patients were grouped into 5 quintiles, Q1; very low risk, Q2; low risk, Q3; intermediate risk, Q4; high-risk, and Q5; very high risk. Incidence rates of major and minor bleeding events and cardiac mortality were assessed during admission and after 1 and 12 months of follow up.

Statistical analysis

Data were described using mean values ± standard deviation (SD) for continuous variables, frequencies, and percentages for categorical variables. The differences between proportions were tested using chi-square tests and the differences between two means were analyzed using independent t-test. Multivariate analysis of factors associated with in-hospital major bleeding was performed using logistic regression analysis. The variables were included in the model step by step and those with p<0.10 in the univariate analysis were included in the model. Receiver operating characteristic (ROC) curve analyses were used to examine the overall discriminatory power of CRUSADE BRS to predict in-hospital major bleeding. The overall performance of the CRUSADE BRS was assessed by calculating the area under the curve (AUC). A p value of <0.05 was considered statistically significant. Statistical analyses were performed using the IBM SPSS 20 (SPSS Inc., Chicago, USA).

Results

Patients’ characteristics

The study included 2426 consecutive patients who underwent PCI and were followed up for one year. Follow up information was obtained directly from patients in 92% (clinic visits in
45% and by phone calls in 47%), from primary care physicians in 6%, and from household relatives in 2%.

Their baseline demographic and clinical characteristics at admission are shown in Table 1. Of the whole group, 24.7% were <50 years old, 48% had DM, and 77.4% were overweight or obese. 77.1% had ACS as the admission diagnosis. Table 2 shows the coronary arteriography findings, PCI procedures and indications, and medications used during hospitalization and at discharge. The vascular access was the femoral artery in the majority of procedures. Dual antiplatelet agents and GPI were administered in 99% and 13.5% of patients, respectively. Only 3.3% of patients were treated with thrombolysis.

### Table 1. Demographic, clinical, and angiographic characteristics of the study patients

| Feature                                             | n    | %   |
|-----------------------------------------------------|------|-----|
| Age, years (mean±SD)                                | 59.0±10.1 |    |
| Females                                             | 500  | 20.6|
| Hypertension                                        | 1511 | 62.3|
| Diabetes mellitus                                   | 1168 | 48  |
| Hypercholesterolemia                                | 1184 | 48.8|
| Current smoker                                      | 1055 | 43.5|
| Past myocardial infarction                          | 263  | 10.8|
| Past stroke                                         | 50   | 2.1 |
| Peripheral arterial disease                         | 21   | 0.9 |
| Prior PCI                                           | 589  | 24.3|
| Prior coronary artery bypass surgery                 | 84   | 3.5 |

### Medications prior to admission

| Medications                                         | n    | %   |
|-----------------------------------------------------|------|-----|
| Aspirin                                             | 1568 | 64.7|
| Clopidogrel                                         | 532  | 22.0|
| Ticagrelor                                          | 16   | 0.7 |
| Oral anticoagulants                                 | 34   | 1.4 |
| Statins                                             | 1266 | 52.2|
| Beta blockers                                       | 1150 | 47.5|
| Renin-angiotensin system blockers                   | 987  | 40.8|
| Antidiabetic agents                                 | 846  | 34.9|
| ST-segment deviation                                | 1181 | 48.6|
| Elevated serum cardiac biomarkers                   | 970  | 40.0|
| LVEF <45%                                           | 302  | 12.5|
| Heart failure on admission                          | 269  | 11.1|

### Diagnosis

| ACS                                                | 1870 | 77.1 |
| STMI                                               | 726  | 29.9 |
| NSTEACS                                            | 306  | 12.6 |
| UA                                                 | 838  | 34.5 |
| Stable coronary syndrome                           | 556  | 22.9 |
| Chronic stable angina                              | 500  | 20.6 |
| Silent ischemia                                     | 56   | 2.3  |

ACS - acute coronary syndrome; LVEF - left ventricular ejection fraction; NSTEACS - non-ST-segment elevation myocardial infarction; PCI - percutaneous coronary intervention; STEMI - ST-segment elevation myocardial infarction; UA - unstable angina

### Table 2. Frequency and distribution of factors related to the PCI procedures

| Feature                                             | n    | %   |
|-----------------------------------------------------|------|-----|
| Number of diseased coronary arteries                |      |     |
| 1 coronary artery                                   | 1417 | 58.4|
| 2 coronary arteries                                 | 718  | 29.6|
| ≥3 coronary arteries                                | 291  | 12.0|
| Number of coronary arteries treated with PCI        |      |     |
| 1 coronary artery                                   | 1732 | 71.4|
| 2 coronary arteries                                 | 568  | 23.4|
| ≥3 coronary arteries                                | 119  | 5.6 |
| Left main coronary artery                           | 28   | 1.2 |
| Saphenous vein graft                                | 25   | 1.0 |

### Indications for PCI

| STEMI                                               | 736  | 30.3 |
| Primary                                             | 398  | 16.4 |
| Rescue                                              | 68   | 2.8  |
| Elective                                            | 270  | 11.1 |
| NSTEACS                                             | 1138 | 46.9 |
| Urgent                                              | 30   | 1.2  |
| Early invasive                                      | 368  | 15.2 |
| Invasive                                            | 740  | 30.5 |
| Stable coronary syndrome                            | 550  | 22.7 |

### Medications during hospitalization

| Aspirin                                             | 2404 | 99.1 |
| Clopidogrel                                         | 1968 | 81.1 |
| Ticagrelor                                          | 455  | 18.8 |
| Thrombolytic agents                                 | 81   | 3.3  |
| Glycoprotein IIb/IIIa inhibitors                    | 327  | 13.5 |
| Heparin                                             | 2362 | 97.4 |
| Antidiabetic agents                                 | 940  | 37.7 |

### Medications on discharge

| Aspirin                                             | 2397 | 99.5 |
| Clopidogrel                                         | 1977 | 82.0 |
| Ticagrelor                                          | 410  | 17.0 |
| Oral anticoagulants                                 | 20   | 0.9  |
| Statins                                             | 2358 | 97.9 |
| Beta blockers                                       | 1924 | 79.8 |
| Renin-angiotensin system inhibitors                 | 1502 | 62.3 |

### Vascular access

| Femoral                                             | 2353 | 97.0 |
| Radial                                              | 54   | 2.2  |
| Brachial                                            | 9    | 0.8  |

ACS - acute coronary syndrome; NSTEACS - non-ST-segment elevation acute coronary syndrome; PCI - percutaneous coronary intervention; STEMI - ST-segment elevation myocardial infarction
The incidence rates of major and minor bleeding events among the studied patients are detailed in Table 3. During the index hospitalization, major and minor bleeding events occurred in 0.95% and 2.6% of patients, respectively. Most of the major bleeding events were transfusion-requiring or associated with an Hct drop (19/23 (82.6%)]. All vascular access bleeding events were minor. In-hospital major bleeding among patients who received thrombolytic agents (2.5%) was not different from that among patients who did not receive thrombolysis (0.9%), \( p=0.39 \). At one year, the incidence rate of major bleeding events was 1.29%, which implied that only a small number of patients had bleeding events after discharge up to 1 year of follow up. Patients who had PCI for ACS had more major bleeding events than patients with stable coronary disease (1.1% vs. 0.5%), but this observation was not significant (\( p=0.53 \)).

### Factors associated with in-hospital major bleeding

The incidence rates of in-hospital major bleeding according to significant variables in univariate analysis are shown in Table 4. Major bleedings during hospitalization were significantly higher among females, patients older than 65 years, and those who have diabetes, hypertension, CrCl <90, or past PCI. Multivariate analysis showed that only two variables were significantly associated with major bleeding: female gender (OR=3.7; 95% CI 1.6, 8.5; \( p=0.002 \)) and past history of cardiovascular disease (OR=2.6; 95% CI 1.1, 5.9; \( p=0.026 \)).

### Major bleeding and cardiac mortality

Patients who had in-hospital major bleeding events had higher cardiac mortality during index hospitalization (13.0% vs. 0.7%, \( p<0.005 \)) and at one year of follow up (13.0% vs. 1.8%, \( p<0.005 \)) compared to those who had no such events.

### Predictive power of CRUSADE BRS

CRUSADE BRS ranged from 1 to 94 with a mean of 23.3 ± 13.8. Patients who developed in-hospital major bleeding had significantly higher CRUSADE score compared to those who had no bleeding (31.9% vs. 22.3%, \( p<0.005 \)). The incidence of major bleeding events in each quintile of the CRUSADE score is shown in Table 5, and ranged from 0.4% in the lowest quintile to 1.8% in the highest quintile. There was a significant increasing trend.

### Table 3. Incidence rates of major and minor bleeding events among the studied patients

| Bleeding events | During admission (2426 patients) | From discharge to 30 days (2387 patients) | From 1 to 6 months (2343 patients) | From 6 to 12 months (2297 patients) | All n |
|----------------|----------------------------------|------------------------------------------|------------------------------------|-------------------------------------|-------|
| Major bleeding | 23 (0.95%)                       | 4 (0.17%)                                | 1 (0.04%)                          | 3 (0.13%)                           | 31    |
| ICH            | 2                                | 0                                        | 0                                  | 1                                   | 3     |
| Retroperitoneal| 2                                | 0                                        | 0                                  | 0                                   | 2     |
| Transfusion-requiring | 3                          | 4                                        | 1                                  | 2                                   | 10    |
| Hematocrit drop| 16                               | 0                                        | 0                                  | 0                                   | 16    |
| Minor bleeding | 64 (2.6%)                        | 10 (0.42%)                               | 1 (0.04%)                          | 2 (0.08%)                           | 77    |
| Vascular access site | 64                           | 8                                        | 1                                  | 2                                   | 75    |
| Hematuria      | 0                                | 2                                        | 0                                  | 0                                   | 2     |

ICH - intracranial haemorrhage

### Table 4. Incidence rates of in-hospital major bleeding according to important and significant variables in univariate analysis

| Variable                  | Major bleeding during admission | \( P \) |
|---------------------------|---------------------------------|---------|
|                          | No | %       | Yes | %       |
| Gender                   |    |         |     |         |
| Male                     | 1914 | 99.4 | 12 | 0.6     | 0.001 |
| Female                   | 489  | 97.8  | 11 | 2.2     |       |
| Age, year                |    |         |     |         |
| \( \leq 65 \)            | 1781 | 99.3  | 12 | 0.7     | 0.017 |
| \( >65 \)               | 622  | 98.3  | 11 | 1.7     |       |
| Diabetes mellitus        |    |         |     |         |
| Yes                      | 1283 | 98.7  | 17 | 1.3     | 0.050 |
| No                       | 1120 | 99.5  | 6  | 0.5     |       |
| Hypertension             |    |         |     |         |
| No                       | 912  | 99.7  | 3  | 0.3     | 0.014 |
| Yes                      | 1491 | 98.7  | 20 | 1.3     |       |
| eGFR                     |    |         |     |         |
| \( <60 \)               | 293  | 98.3  | 5  | 1.7     | 0.017 |
| 60–89                    | 674  | 98.4  | 11 | 1.6     |       |
| \( \geq 90 \)           | 1434 | 99.5  | 7  | 0.5     |       |
| Past PCI                 |    |         |     |         |
| No                       | 1824 | 99.3  | 13 | 0.7     | 0.031 |
| Yes                      | 579  | 98.3  | 10 | 1.7     |       |
| Past CVD                 |    |         |     |         |
| No                       | 1462 | 99.3  | 10 | 0.71    | 0.090 |
| Yes                      | 941  | 98.6  | 13 | 1.4     |       |

CVD - cardiovascular disease; eGFR - estimated glomerular filtration rate; PCI - percutaneous coronary intervention
in the rate of bleeding with the higher quintiles of the CRUSADE score. ROC analysis showed that the CRUSADE score has a high ability to predict major bleeding events.

Furthermore, cardiac mortality during index hospitalization was higher among patients who had major bleeding and high scores (mortality 0% in the three lower quintiles, 14.3% in the high quintile, and 22.2% in the very high quintile, p-trend <0.0001).

Mortality among patients who had major bleeding events from hospital admission to one year of follow up was significantly higher than those who did not have major bleeding event (Table 6).

### Discussion

This is the first study that evaluated the incidence, risk factors, and impact on prognosis of major bleeding events, and the CRUSADE BRS predictability in Jordanian patients undergoing PCI in Jordan. The main findings were: (1) major bleeding events are uncommon but are associated with higher in-hospital and one-year cardiac mortality compared with patients who did not have major bleeding, (2) most of the major bleeding events occurred during hospitalization, (3) several factors were associated with an increased risk of bleeding, but only female gender and past history of cardiovascular disease (CVD) were independent predictors of major bleeding in the multivariate analysis, and (4) CRUSADE BRS was highly predictive for the incidence of in-hospital major bleeding events.

### Major bleeding events

Traditionally, the outcome after PCI has been evaluated by measuring the classical 3 endpoints of death, MI, and urgent repeat revascularization. Recently, bleeding has been integrated in outcome analysis of clinical studies and registries because peri-procedural bleeding in patients undergoing PCI is associated with an increased risk of recurrent ischemic complications and can adversely affect both short- and long-term mortality (1-4, 13-17).

This study enrolled patients who underwent PCI; a risk factor for bleeding by itself. Moreover, the majority of the enrolled patients (77%) had ACS; another risk factor for bleeding and most of the patients who had PCI for stable coronary disease (23%) had several risk factors associated with increased bleeding risk. Despite this clinical background, the incidence of major bleeding events was low. It is essential to adopt strategies that can reduce the incidence of bleeding, including the usage of a BRS to estimate the risk of major bleeding events and identify high-risk patients, use of appropriate antiplatelet and antithrombotic agents with maximal antithrombotic profile and minimal bleeding risk, choice of arterial access site, types and sizes of devices used in the PCI procedure, ACT monitoring, and closer surveillance for bleeding after the procedure (18-25).

The list of risk factors for bleeding in patients admitted with ACS or who underwent PCI includes old age, female gender, hypertension, DM, lower body weight, prior vascular disease [PAD, chronic renal disease and heart failure, and lower body weight. We observed a sharp decrease in the incidence of major bleeding events after discharge. Most of these events were minor vascular access hematomas that occurred in the first month of follow up.

The association of bleeding with excess long-term mortality in this study concurs with other studies and implies that bleeding is not simply a side effect of the medications and PCI procedure, or an acute event with no long-term prognostic impact (1, 25, 31). The excess bleeding-related mortality is multifactorial. These factors include the common risk factors mortality and bleeding share (age, diabetes mellitus, hypertension, past history of CVD, and renal insufficiency), hemodynamic effects of massive bleeding, higher mortality associated with intracranial bleeding, neurohormonal activation associated with hypotension, and bleeding-related imaging procedures and surgical interventions under general anesthesia that may independently increase cardiac mortality (32-38).

### CRUSADE bleeding risk score

Clinical studies have shown that the CRUSADE BRS has a relatively high accuracy for estimating bleeding risk by incorpo-
rating admission and treatment variables. Although age is one of the predictors of major bleeding that is not directly considered in calculating the risk score, it is incorporated in calculating the CrCl. Each of the bleeding risk scores in clinical use has been utilized in specific patient population, including STEMI patients treated with fibrinolysis (GUSTO score) (39), STEMI and NSTEMI patients (GRACE score) (9), ACS patients planned to have urgent or early intervention (Phase III ACUITY study) (7), elective or urgent PCI via the femoral artery access (5), PCI with combination antiplatelet and antithrombotic agents (REPLACE 2 study) (40), and NSTEMI patients (CRUSADE study) (6).

The CRUSADE BRS was originally developed from NSTEMI patients’ data, but its predictive value was unchanged when patients with UA were included. Moreover, analysis of the ACTION Registry-GWTG suggested that the CRUSADE BRS can be applied in STEMI patients (41). The CRUSADE BRS evaluated the score’s predictability in in-hospital major bleeding events and mortality. Our study further demonstrated that this predictability persists up to one year after discharge, similar to other studies (25). The observed high predictability for major bleeding events of the CRUSADE BRS supports its expanded applicability in other geographical regions than those where the score was developed.

Study limitations

This registry had limitations inherent to observational studies (42). It may be subject to selection bias, collection of non-randomized data, and missing or incomplete information. Participation was voluntary and the enrolment of consecutive patients was encouraged, but this was not verified, as it is the case with similar registries (43). The accuracy of recall of the patients or their relatives of major events, such as major bleeding, is unlikely to be underestimated. The registry included high volume tertiary care center; thus, it may not fully represent the PCI practice and outcome in all areas in the country or region.

Conclusions

Major bleeding events were uncommon in this Jordanian registry of a contemporary cohort of patients undergoing PCI but were associated with a higher mortality rate compared with those who did not have major bleeding events. CRUSADE BRS was highly predictive of the incidence of major bleeding events. We recommend incorporating CRUSADE BRS in the care of patients undergoing PCI to identify high-risk patients for bleeding events.

Conflict of interest: None declared.

Peer-review: Externally peer-reviewed.

Authorship contributions: Concept – M.J., Y.K., A.H., L.N., L.T.; Design – M.J., A.H., S.G., H.A., E.H.; Supervision – M.J., Y.K., A.H., S.G., L.N., H.A., E.H., L.T.; Fundings – Novartis; Materials – M.J., A.H., O.O., S.G., L.N., H.K., E.H., L.T.; Data collection &/or processing – M.J., Y.K., A.H., O.O., S.G., D.O.; Analysis &/or interpretation – M.J., Y.K., A.H., O.O., D.O.; Literature search – M.J., A.H., O.O., A.A.H.; Writing – M.J., A.H., L.N., H.K.; Critical review – M.J., Y.K., A.H., H.K.

References

1. Erdem G, Flath M. Assessing bleeding risk in acute coronary syndromes. Rev Esp Cardiol 2012; 65: 4-8.
2. Subherwal S, Peterson ED, Dai D, Thomas L, Messenger JC, Xian Y, et al. Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data Cath-PCI Registry. J Am Coll Cardiol 2012; 59: 1861-9.
3. Chhatriwalla AK, Amin AP, Kennedy KF, House JA, Cohen DJ, Rao SV, et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA 2013; 309: 1022-9.
4. Kikkert WJ, Zwinderman AH, Vis MM, Baan J Jr, Koch KT, Peters RJ, et al. Timing of mortality after severe bleeding and recurrent myocardial infarction in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2013; 6: 391-8.
5. Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 28: 1936-45.
6. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et al. Baseline risk of major bleeding in non-ST-segment elevation myocardial infarction: the CRUSADE (Can Rapid Risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score. Circulation 2009; 119: 1973-82.
7. Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, et al. Association of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009; 30: 1457-66.
8. Ariza-Sole A, Salazar-Mendiguchia J, Lorente V, Sanchez-Salado JC, Romaguera R, Ferreiro JL, et al. Predictive ability of bleeding risk scores in the routine clinical practice. Eur Heart J Acute Cardiovasc Care 2015; 4: 205-10.
9. Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815-23.
10. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736-47.
11. O’Gara PT, Kushner FG, Asch DD, Casey DE, Chung MK, de Lemos JA, et al. FACC 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e130-e140.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
13. Naruse Y, Sato A, Hoshi H, Takeyasu N, Kakefuda Y, Ishibashi M, et al. Cardiovascular Assessment Study (ICAS) Registry. Triple anti-thrombotic therapy is the independent predictor for the occurrence of major bleeding complications. Analysis of percent time in thera-
14. Abraham NS, Hartman C, Richardson P, Castillo D, Street Jr. RL, Naik AD. Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients. Circulation 2013; 128: 1869-77.

15. Taylor J. Updated ESC Guidelines for managing patients with suspected non-ST-elevation acute coronary syndrome. Eur Heart J 2011; 32: 2909-10.

16. Fox KA, Carruthers K, Steg PG, Avezum A, Granger CB, Montale- scot G, et al; GRACE Investigators. Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events. Eur Heart J 2010; 31: 667-75.

17. Becker RC, Bassand JP, Budaj A, Wijndal DM, James SK, Cornel JH, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and pa- tient Outcomes (PLATO) trial. Eur Heart J 2011; 32: 2933-44.

18. Gehani AA, Al-Hinai AT, Zaubid M, Almahmeed W, Hasani MR, Yusu- sfahi AH, et al, for the INTERHEART Investigators in Middle East. Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study. Eur J Prev Cardiol 2014; 21: 400-10.

19. Hammoudeh AJ, Izraiq M, Hamdan H, Tarawneh H, Harassis A, Tab- balat R, et al. High-sensitivity C-reactive protein is an independent predictor of future cardiovascular events in Middle Eastern patients with acute coronary syndrome. CRP and prognosis in acute coronary syndrome. International Journal of Atherosclerosis 2008; 3: 50-5.

20. Hammoudeh A, Echtay A, Ghanem Y, Haddad J; CEPHEUS LE- VANT Survey Investigators. Achieving low-density lipoprotein cho- lesterol treatment goals among dyslipidemic individuals in the Le- vant: the CENTralized Pan-Levant survey on the Undertreatment of hypercholesterolemia (CEPHEUS) study. Curr Med Res Opin 2014; 30: 1957-65.

21. Marso SP, Amin AP, Housen JA, Kennedy KF; Spertus JA, Rao SV, et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percuta- neous coronary intervention. JAMA 2010; 303: 2156-64.

22. Rao SV, O’Grady K, Pieper KS, Granger CB, Newby LV, Van de Werf F, et al. Impact of bleeding severity on clinical outcomes among pa- tients with acute coronary syndromes. Am J Cardiol 2005; 96: 1200-6.

23. Verheugt FW, Steinhibl RS, Hamon M, Darius H, Steg PG, Valgimigli M, et al. Incidence, prognostic impact, and influence of antithrom- bolytic therapy on access and non-access site bleeding in percuta- neous coronary intervention. J Am Coll Cardiol 2011; 4: 191-7.

24. Halg C, Brunner-La Rocca HP, Kaiser C, Jeger R, Osswald S, Pfisterer M, et al; BASKET investigators. Early and late increased bleeding rates after angioplasty and stenting due to combined antiplatelet and anticoagulant therapy. EuroIntervention 2009; 5: 425-31.

25. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Scho- mig A, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51: 690-7.

26. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J 2015;36:1762-71.

27. Hasin T, Markiewicz W, Hammeman H, Aronson D. Prevalence and prognostic significance of transient, persistent, and new-onset anemia after acute myocardial infarction. J Am Coll Cardiol 2009; 104: 486-91.

28. Kwok CS, Sherwood MW, Watson SM, Nasir SB, Sperrin M, Nolan J, et al. Blood transfusion after percutaneous coronary interven- tion and risk of subsequent adverse outcomes. J Am Coll Cardiol Intv 2015; 8: 436-46.

29. Valente S, Lazzeri C, Chistouri M, Sori A, Giglioli C, Gensini GF. Prior and new onset anemia in ST-elevation myocardial infarction: a dif- ferent prognostic role? Intern Emerg Med 2011; 6: 329-36.

30. Pham PA, Pham PT, Pham PC, Miller JM, Pham PM, Pham SV. Implications of bleeding in acute coronary syndrome and percutaneous coronary intervention. Vasc Health Risk Manag 2011; 7: 551-67.

31. Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, Badimon L, et al. Bleeding in acute coronary syndromes and percutaneous coro- nary interventions: Position paper by the Working Group on Throm- bosis of the European Society of Cardiology. Eur Heart J 2011; 32: 1854-64.

32. Robinson SD, Janssen C, Fretz EB, Chase A, Della Siega A, Carere RG, et al. Non-red blood cell transfusion as a risk factor for mor- tality following percutaneous coronary intervention. Int J Cardiol 2012; 157: 169-73.

33. Pilgrim TM, Wenaweser P. Impact of bleeding on clinical outcome in patients undergoing PCI. Eur Heart J 2010; 31(Suppl 1): 658.

34. Sabatine MS, Morrow DA, Guigliano RP, Burton PB, Murphy SA, McCabe CH, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111: 2042-9.

35. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Ad- verse impact of bleeding on prognosis in patients with acute coro- nary syndrome. Circulation 2006; 114: 774-82.

36. Dangas GD, Mehran R, Nikolsky E, Claessen BE, Lansky AJ, Brodie BR, et al. Effect of switching anti-thrombotic agents for primary anti- glycoplasy in acute myocardial infarction. The HORIZONS-SWITCH analysis. J Am Coll Cardiol 2011; 57: 2309-16.

37. Dauerman HL, Rao SV, Resnic FS, Applegate RJ. Bleeding avoid- ance strategies. Consensus and controversy. J Am Coll Cardiol 2011; 58: 1-10.

38. Manoukian SV. The relationship between bleeding and adverse outcomes in ACS and PCI: pharmacologic and nonpharmacologic modification of risk. J Invasive Cardiol 2010; 22: 132-41.

39. Yu J, Baber U, Kini A, Vlachojannis G, Sartori S, O’Neill B, et al. Comparison of bleeding definitions, BARC, GUSTO, TIMI and VARC in patients undergoing balloon aortic valvuloplasty: results from a two-center registry. J Am Coll Cardiol 2012; 59: E65.

40. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleinman NS, Jackman JD, et al. REPLACE-2 Investigators. Bivalirudin and provisional gly- coprotein IIb/IIIa blockade during percutaneous coronary interven- tion: REPLACE-2 randomized trial. JAMA 2003; 289: 853-63.

41. Mathews R, Peterson ED, Chen AY, Wang TY, Chin CT, Fonarow GC, et al; European Society of Cardiology. Management and outcome of patients with established coronary artery disease: Euro Heart Survey on coronary revascularization. Eur Heart J 2005; 26: 1169-79.